“The Alzheimer’s Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Alzheimer’s Disease pipeline products will significantly revolutionize the Alzheimer’s Disease market dynamics”
The Alzheimer’s Disease market report provides current treatment practices, Alzheimer’s Disease emerging drugs, market share of individual therapies, and current and forecasted 7MM Alzheimer’s Disease market size from 2019 to 2032. The report also covers current Alzheimer’s Disease treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Key Takeaways from the Alzheimer’s Disease Market Research Report
- According to DelveInsight’s estimates, among the 7MM, the US had the largest Alzheimer’s disease market share, with a revenue of USD 1,751.7 million in 2022. The Alzheimer’s disease market size in the US will increase at a significant CAGR due to increasing awareness of the disease and the launch of the emerging therapy.
- The leading companies working in the Alzheimer’s Disease Market include Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and others.
- Promising Alzheimer’s Disease Pipeline Therapies in the various stages of development include PM012, Lecanemab 2.5 mg/kg, Aricept (donepezil SR 23 mg), AL002, Rivastigmine transdermal patch, Simufilam, and others.
- September 2023: Alector Inc. announced a study of phase 2 clinical trials for AL002. A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer’s Disease.
- September 2023: Cassava Sciences Inc. announced a study of phase 3 clinical trials for Simufilamv. The primary objective of this study is to investigate the safety and efficacy of simufilam (PTI-125) in enhancing cognition and slowing cognitive and functional decline following 52-week, repeat-dose oral administration in participants with mild-to-moderate AD.
Discover more about therapies set to grab major Alzheimer’s Disease Market Share @ Alzheimer’s Disease Market Size
Alzheimer’s Disease Overview
Alzheimer’s disease, the most common type of dementia, is a progressive neurodegenerative disorder with a multifactorial pathogenesis. It is characterized by the gradual decline in cognitive and functional abilities, with individuals eventually losing the ability to undertake everyday tasks and function independently. Symptoms, for most people, first appear in their mid-60s. However, early disease may manifest in quadragenarians as well.
Alzheimer’s Disease Epidemiology Segmentation in the 7MM
- Total Alzheimer’s Disease Diagnosed prevalent cases
- Alzheimer’s Disease Age-specific cases
- Alzheimer’s Disease Gender-specific cases
- Alzheimer’s Disease Severity-specific cases
Download the report to understand which factors are driving Alzheimer’s Disease Epidemiology Trends @ Alzheimer’s Disease Epidemiological Insights
Alzheimer’s Disease Marketed Drugs
- ADUHELM (aducanumab): Biogen and Eisai
- LEQEMBI (lecanemab): Biogen and Eisai
Alzheimer’s Disease Emerging Drugs
- NE3107: BioVie
- Donanemab (LY3002813): Eli Lilly
- Simufilam (PTI-125): Cassava Sciences
- Hydromethylthionine mesylate/TRx0237: TauRx Therapeutics
- Fosgonimeton (ATH-1017): Athira Pharma
- Buntanetap: Annovis Bio
- ANAVEX2-73 (blarcamesine): Anavex Life Sciences
To know more about Alzheimer’s Disease Treatment options, visit @ Alzheimer’s Disease Drugs
Alzheimer’s Disease Drugs Market
Alzheimer’s disease, the most common type of dementia, is a progressive neurodegenerative disorder with a multifactorial pathogenesis. It is characterized by a gradual decline in cognitive and functional abilities, with individuals eventually losing the ability to undertake everyday tasks and function independently. Symptoms of Alzheimer’s disease, for most people, first appear in their mid-60s. However, early disease may manifest in quadragenarians as well. Early diagnosis becomes difficult with the exact cause mostly unknown and limited early manifestation. The multifactorial nature of the disease further compounds this. Earlier diagnosis is important for enabling symptomatic therapies, treating behavioral symptoms, and adopting lifestyle changes.
Alzheimer’s Disease Market Outlook
The drugs currently available to treat many of the symptoms associated with dementia are working by increasing activity levels of some brain neurotransmitters, such as acetylcholine, serotonin, and noradrenaline, or by reducing the activity of other neurotransmitters, such as glutamate and dopamine. Due to associated side effects, it is also important to personalize dementia symptomatic therapeutics considering patients’ comorbidities and their respective therapies. Effects on cardiac function, drug elimination, and other interactions should be assessed case by case.
Learn more about the Alzheimer’s Disease Pipeline Therapies in clinical trials @ Alzheimer’s Disease Market Landscape
Scope of the Alzheimer’s Disease Market Research Report
- Coverage- 7MM
- Study Period- 2019-2032
- Alzheimer’s Disease Companies- Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and others.
- Alzheimer’s Disease Pipeline Therapies- PM012, Lecanemab 2.5 mg/kg, Aricept (donepezil SR 23 mg), AL002, Rivastigmine transdermal patch, Simufilam, and others.
- Alzheimer’s Disease Market Dynamics: Alzheimer’s Disease Market Drivers and Barriers
- Alzheimer’s Disease Market Access and Reimbursement, Unmet Needs, and Future Perspectives
Discover more about Alzheimer’s Disease Drugs in development @ Alzheimer’s Disease Ongoing Clinical Trials Analysis
Table of Content
1. Key Insights
2. Report Introduction
3. Alzheimer’s Disease Market Overview at a Glance
4. Methodology of Alzheimer’s Disease Epidemiology and Market
5. Executive Summary of Alzheimer’s Disease
6. Key events
7. Disease Background and Overview
8. Alzheimer’s Disease Patient Journey of Alzheimer’s Disease
9. Alzheimer’s Disease Epidemiology and Patient Population
10. Alzheimer’s Disease Marketed Drugs
11. Emerging Alzheimer’s Disease Therapies
12. Alzheimer’s Disease: The Seven Major Market Analysis
13. Alzheimer’s Disease KOL views
14. SWOT Analysis
15. Alzheimer’s Disease Unmet Needs
16. Alzheimer’s Disease Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking